HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Raises Price Target to $65
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and raises the price target from $39 to $65.
45 Biggest Movers From Yesterday
Gainers
Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking.
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
Bicycle Therapeutics plc (NASDAQ:BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion…
Bicycle Therapeutics Reports Interim Results From Phase 1 Trial OF BT5528
- BT5528 Phase I anti-tumor activity observed in late line patients, with 2 partial responses out of 2 urothelial cancer patients dosed and an 80% disease control rate in 5 EphA2-positive ovarian cancer patients,
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
B. Riley Securities Initiates Coverage On Bicycle Therapeutics with Buy Rating, Announces Price Target of $56
B. Riley Securities analyst Kalpit Patel initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Buy rating and announces Price Target of $56.